▪︎ Effective treatment for active patients with relapsing remitting multiple sclerosis.
▪︎ First orally administered treatment with more than 10 years of experience in real life.
▪︎ Demonstrated bioequivalence in a study of comparative bioavailability versus the reference product, carried out in Ontario, Canada.
FORMULATIONS:
Package containing 28 hard capsules.
Each capsule contains: 0.5 mg Fingolimod as 0.56 mg Fingolimod hydrochloride.
The material on this website is oriented to healthcare professionals only. It aims to provide information on how to use these medications efficiently, and to spread the knowledge of these products. This information does not substitute medical diagnosis, advice and indication. Biosidus recommends asking a doctor first.
The texts referring to our prescription drugs abide by the National Administration of Drugs, Foods and Medical Devices (ANMAT) in the Argentine Republic approved guidelines.